When Roivant Sciences CEO Matt Gline held a meeting with pharma giant Roche at the J.P. Morgan Healthcare Conference at the beginning of the year, he expected a brief one-on-one conversation with a member of the Swiss pharma’s team.
Instead, thirteen people showed up to the meeting “and it evolved from there,” Gline said last week, just a couple days after Roche announced a $7 billion deal to buy Roivant subsidiary Telavant, picking up a promising drug candidate for inflammatory bowel disease.
The deal, fostered by Telavant chairman and CEO Frank Torti, was a case of good science and good business colliding, Torti said.
“There’s a lot of value in this ecosystem for doing things that really matter,” Torti said. “And that’s where we focus.”
https://www.pharmavoice.com/news/roivant-roche-telavant-7b-deal-immunology/698249/
This was for an IBD therapy as reported here last week with holders placing huge hopes on IHL-42X perhaps in isolation to the other pipeleines,
forgetting maybe that IHL-675A has far greater market potential than IHL-42X.
IHL-675A (R/A) is about to commence phase 2 Trials, this will be interesting to follow as it will be indicative IMO for IHL-675A (IBD)
https://www.incannex.com/clinical-trail/ihl-675a-inflammatory-bowel-disease/
Just as aside ....shows how important the JP Morgan Healthcare conference is @von
GLAH